1、Andrew Boyle,MDAssociate Professor of MedicineMedical Director of Heart Failure,Cardiac Transplantation,and Mechanical Circulatory SupportDivision of CardiologyUniversity of MinnesotaMancini D et al.Circulation 1991;83:778-786.Group 1:peak VO2 14Group 3:rejected for OHTx%of TransplantsJ Heart Lung T
2、ranspl.2004;23:796-803.J Heart Lung Transplant 2008;27:937-983.Graft Survival for All Heart Transplants(n=645)According to Adult and Pediatric Transplants0123456789100.00.20.40.60.81.0Log-Rank p 0.001Wilcoxon p 6 months192 12 months67 24 months16*As of 3/3/09Boyle A et al.ACC Late Breaking Clinical
3、Trial 2009.Lindenfeld J et al.Circulation 2007;115:204-212.Lindenfeld J et al.Circulation 2007;115:204-212.Boyle A et al.Presented at ACC 2008.Test to determine candidacy for transplant is metabolic stress test Median survival post-transplant is 10 years Frequency of transplantation is declining Long term inotropic therapy not very successful Continuous flow VADs show good long term survival with reduced adverse events VADs now approved for BSA as low as 1.2 CRT for NYHA Class IV heart failure not terribly effective
